Condition: Melanoma Stage IV · Melanoma Stage III · Sponsor: Pierre Fabre Pharma GmbH
BERING-MELANOMA - designed as a prospective, longitudinal, non-interventional study - investigates real-world effectiveness, quality of life, safety and tolerability of encorafenib plus binimetinib in unresectable advanced or metastatic BRAF(Rapidly Accelerated Fibrosarcoma isoform B)-V600-mutant malignant melanoma after commercial availability of these two products in Germany, Austria and Switzerland. The study focusses on the documentation of the first and second line setting (i.e. after one line of prior checkpoint inhibition) by documenting patients treated according to the SmPC (Summary of Product Characteristics).
This description comes directly from the study's public registry record.
Christian A Rosé, MD · +49 761 45261 · bering_de@pierre-fabre.com
Andrea Schmidt, MSc · +49 641 94436 · ansc@alcedis.de
Always discuss trial participation with your own doctor first.
| 11 | Graz, Austria | Recruiting |
| 13 | Innsbruck, Austria | Recruiting |
| 14 | Klagenfurt, Austria | Recruiting |
| 10 | Linz, Austria | Recruiting |
| 3 | Linz, Austria | Recruiting |
| 12 | Salzburg, Austria | Recruiting |
| 22 | Vienna, Austria | Recruiting |
| 53 | Vienna, Austria | Recruiting |
| 23 | Wiener Neustadt, Austria | Recruiting |
| 45 | Ahaus, Germany | Recruiting |
| 8 | Aschaffenburg, Germany | Recruiting |
| 56 | Augsburg, Germany | Recruiting |
+ 47 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04045691